Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for dental industry researchers · Wednesday, December 4, 2024 · 765,990,844 Articles · 3+ Million Readers

Travere Therapeutics to Present at Upcoming Investor Conferences

/EIN News/ -- SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management will present in the following upcoming investor conferences in December:

7th Annual Evercore HealthCONx Conference
Tuesday, December 3, 2024, at 10:00 a.m. ET

Citi 2024 Global Healthcare Conference
Wednesday, December 4, 2024, at 2:30 p.m. ET

Live webcasts of the presentations will be accessible on the Investor page of Travere’s website at ir.travere.com/events-presentations, and replays will be available for up to 30 days following each event.

About Travere Therapeutics
At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop, and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com.

Contact:

Investors:
888-969-7879
IR@travere.com
Media:
888-969-7879
mediarelations@travere.com

Primary Logo

Powered by EIN News

Distribution channels: Culture, Society & Lifestyle, Healthcare & Pharmaceuticals Industry ...

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Submit your press release